Throwing in the towel on Trimeris

Trimeris reported first quarter sales of its only drug Fuzeon declining 34% compared to the same period a year ago. In previous quarters, sales outside North America managed to offset the losses domestically. That is not the case anymore as sales outside of North America also suffered a precipitous drop of 26%.

The company might able to work out another favorable agreement with their partner Roche in which they will receive some credit for COGS miscalculations as they have done in the past, and they might finish the Phase 1 trials on their next generation fusion inhibitor (TRI-1144) and sell the comapany, but I am not waiting around for that.

I sold the position yesterday, it's time to move on.